Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;61(5):575-579.
doi: 10.1002/mus.26804. Epub 2020 Jan 21.

Rituximab in refractory chronic inflammatory demyelinating polyneuropathy

Suraj A Muley  1 , Bill Jacobsen  1 , Gareth Parry  2 , Uzma Usman  1 , Erik Ortega  1 , David Walk  2 , Jeff Allen  2 , Mamatha Pasnoor  3 , Matthew Varon  3 , Mazen M Dimachkie  3
Affiliations

Rituximab in refractory chronic inflammatory demyelinating polyneuropathy

Suraj A Muley et al. Muscle Nerve. 2020 May.

Abstract

Introduction: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a disorder in which early effective treatment is important to minimize disability from axonal degeneration. It has been suggested that some patients with CIDP may benefit from rituximab therapy, but there is no definitive evidence for this.

Methods: Baseline and post-rituximab-therapy neuromuscular Medical Research Council (MRC) sum scores, Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, and functional status were assessed in 11 patients with refactory CIDP.

Results: The MRC sum score, INCAT disability score, and functional status improved in all patients after rituximab therapy.

Discussion: Our study provides evidence of the efficacy of rituximab therapy in at least some patients with CIDP. A placebo-controlled study to assess the effectiveness of rituximab therapy in CIDP with and without nodal antibodies is required to identify disease markers that predict responsiveness.

Keywords: CIDP; neuropathy; refractory; rituximab; treatment.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. Muley SA, Parry GJ. Inflammatory demyelinating neuropathies. Curr Treat Options Neurol. 2009;11(3):221-227.
    1. Querol L, Siles AM, Alba-Rovira R, et al. Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. Sci Rep. 2017;7(1):14411.
    1. Querol L, Rojas-Garcia R, Diaz-Manera J, et al. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins. Neurol Neuroimmunol Neuroinflamm. 2015;2(5):e149.
    1. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11(2):136-141.
    1. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain. 1996;119(Pt 4):1067-1077.

MeSH terms

LinkOut - more resources